Investor presentation

RNS Number : 8472L
Shield Therapeutics PLC
15 January 2021
 

 

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

 

Investor presentation

 

London, UK, 15 January 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces it will present at the Shares and AJ Bell Investor Evening Webinar, providing an overview of the business and progress being made by the Company.

 

Tim Watts, Chief Executive Officer, will present online at the Shares Spotlight webinar on Wednesday 20 January 2021. The event starts at 18.00 and Tim will be presenting at 18.55. Investors can register to attend here: https://bit.ly/3sjqqiI  

 

No new material information will be disclosed at the event and the presentation will be made available on the Company website shortly after the events here: https://www.shieldtherapeutics.com/investors/presentations .  

 

 

For further information please contact:

 

Shield Therapeutics plc

www.shieldtherapeutics.com

Tim Watts, CEO

+44 (0)20 7186 8500

Lucy Huntington-Bailey, Company Secretary and General Counsel

+44 (0)19 1511 8500

 

Nominated Adviser and Joint Broker

 

Peel Hunt LLP

 

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

 

Joint Broker

finnCap Ltd 

Geoff Nash/Matt Radley/Alice Lane 

 

 

+44 (0)20 7220 0500

 

 

 Financial PR & IR Advisor

 

Walbrook PR

+44 (0)20 7933 8780 or  shield@walbrookpr.com

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

 

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel,  non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer ® in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABAMLTMTIBMRB
UK 100

Latest directors dealings